Welcome to Paid Research Studies




  • Condition:   Sickle Cell Disease
    Intervention:   Drug: Alemtuzumab intravenously, low dose total body irradiation, Sirolimus
    Sponsors:   Allistair Abraham, MD;   Alberta Children's Hospital;   The Hospital for Sick Children;   Levine Children's Hospital
    Recruiting

  • Condition:   Inherited Immune Deficiencies
    Interventions:   Drug: Fludarabine;   Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine;   Drug: Sirolimus or equivalent based on response;   Drug: Granulocyte Colony Stimulating Factor (G-CSF);   Other: hematopoietic progenitor cells
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Conditions:   Idiopathic Pulmonary Fibrosis;   Emphysema or COPD
    Interventions:   Biological: CD3/CD19 negative hematopoietic stem cells;   Drug: Rituximab;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Thiotepa;   Drug: G-CSF;   Drug: Hydroxyurea
    Sponsor:   Paul Szabolcs
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Non Hodgkins Lymphoma;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia;   Hemophagocytic Lymphohistiocytosis (HLH);   Familial Hemophagocytic Lymphohistiocytosis (FLH);   Viral-associated Hemophagocytic Syndrome (VAHS);   X-linked Lymphoproliferative Disease (XLP)
    Interventions:   Drug: Ara-C;   Drug: Cyclophosphamide;   Biological: Campath-1H;   Radiation: Total Body Irradiation;   Procedure: Stem Cell Infusion
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting

  • Condition:   Crohn's Disease
    Interventions:   Biological: autologous CD34-selected peripheral blood stem cells transplant;   Drug: Alemtuzumab;   Drug: ATG;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: G-CSF;   Drug: Mesna
    Sponsor:   Paul Szabolcs
    Recruiting

  • Condition:   Multiple Sclerosis, Relapsing-Remitting
    Interventions:   Drug: Early Highly Effective Therapies Group;   Drug: Escalation Therapies Group
    Sponsors:   The Cleveland Clinic;   University of Nottingham
    Recruiting